Progyny (NASDAQ:PGNY – Get Rating) and Lisata Therapeutics (NASDAQ:LSTA – Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Progyny and Lisata Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Progyny and Lisata Therapeutics' revenue, earnings per share and valuation.

Institutional and Insider Ownership

86.1% of Progyny shares are owned by institutional investors. Comparatively, 6.0% of Lisata Therapeutics shares are owned by institutional investors. 14.0% of Progyny shares are owned by insiders. Comparatively, 2.2% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Progyny and Lisata Therapeutics, as reported by MarketBeat.com.

Progyny presently has a consensus target price of $54.33, suggesting a potential upside of 76.41%. Lisata Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 500.00%. Given Lisata Therapeutics' higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than Progyny.

Volatility & Risk

Progyny has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Summary

Progyny beats Lisata Therapeutics on 11 of the 12 factors compared between the two stocks.

About Progyny

(Get Rating)

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

About Lisata Therapeutics

(Get Rating)

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.